HEALTHCARE RESOURCE UTILIZATION AND RELATED COSTS IN PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (ILDS)

Author(s)

Olson A1, Hartmann N2, Patnaik P3, Garry E4, Bohn R5, Singer D3, Baldwin M2, Wallace L3
1National Jewish Health, Denver, CO, USA, 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 3Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 4Aetion Inc., Boston, MA, USA, 5Bohn Epidemiology, BOSTON, MA, USA

OBJECTIVES

The economic burden of progressive fibrosing ILD (PF-ILD) is poorly characterized. We aimed to examine healthcare resource utilization (HRU) and related costs associated with PF-ILD.

METHODS

We analyzed IBM® MarketScan® claims data (October 2011–September 2015) for patients aged ≥18 years with fibrosing ILD diagnosis defined as a new lung fibrosis claim (after 365 days continuous enrolment) followed by a second claim within 30–365 days, using the second claim as the diagnosis date. PF-ILD was defined on or after fibrosing ILD diagnosis upon occurrence of any proxies for progression (index) (e.g ≥2 pulmonary function tests within 90 days, ≥2 HRCTs within 1 year or oxygen use). HRU and related costs (mean±SD) were summed during the baseline period (before diagnosis of PF-ILD) and the 1-year follow-up period after PF-ILD diagnosis (for patients with sufficient follow-up).

RESULTS

Among 128,231 patients with a lung fibrosis claim, 23,577 (18%) had a second claim required for inclusion, and of these 14,722 patients were classified as having PF-ILD (based on proxies for progression).

Among these PF-ILD patients, there was a higher mean (±SD) number of outpatient visits (including services) during 1-year follow-up (n=5,840; 41.89 [30.15]) than during baseline (25.70 [20.90]). Mean (±SD) number of inpatient admissions was 0.69 (1.18) during follow-up and 0.51 (0.92) during baseline, including more ICU admissions and respiratory-related hospitalizations. Mean total costs were higher during follow-up (n=5,815; $54,215 [116,833]) than during baseline ($37,340 [74,323]). This trend was similar for both inpatient costs (follow-up: $20,746 [88,880]; baseline: $14,883 [53,404]) and outpatient costs ($24,711 [51,429] and $17,075 [37,987]).

CONCLUSIONS

Among patients with PF-ILD, HRU and related costs, particularly relating to outpatient visits, were higher during 1-year follow-up than the baseline period. This study provides much-needed insights into HRU and costs in patients with a progressive phenotype of chronic fibrosing ILD.

Conference/Value in Health Info

2020-05, ISPOR 2020, Orlando, FL, USA

Code

PRS25

Topic

Economic Evaluation, Real World Data & Information Systems

Topic Subcategory

Health & Insurance Records Systems

Disease

Respiratory-Related Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×